On August 11, 2020 Revive Therapeutics (RVV.C) announced that it has received the first set of orally dissolvable thin film strips initially to be used to deliver psilocybin and subsequently additional psychedelic-derived medicines.

RVV is a specialty life sciences company focused on the R&D of therapeutics for medical needs and rare disorders.

Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin.

“The use of mind-altering mushrooms has pervaded human society since long prior to the birth of civilization,” states Double Blind Magazine.

“Psilocybin has been shown by Functional Magnetic Resonance Imaging (fMRI) to create a state of hyperconnectivity between brain networks, foster an increase in neurogenesis (the creation of brain cells), and drastically alter thought pathways,” the magazine continued.

At a recent staff meeting, Equity Guru principal Chris Parry revealed that he has eaten psilocybin mushrooms multiple times in this summer, and the experiences “made it very clear what was important, and what was not important”.

The jury is still out on the therapeutic benefits of “magic mushrooms” – but a steady flow of positive clinical studies and anecdotal field reports has begun to move the regulatory needle.

“Four terminally ill Canadians have won the right to take psychedelic drugs to treat end-of-life anxiety and distress,” reports the UK’s Sky News on August 10, 2020, “They will be allowed to take the hallucinogenic drug psilocybin, derived from magic mushrooms.”

Canada‘s health minister Patty Hajdu approved the landmark application three months after the initial request was made.”

“We see great promise in delivering psychedelic-based medicines to treat various diseases and disorders,” stated Michael Frank, CEO of Revive, “We look forward to unveil the final prototype in the coming weeks.”

RVV has identified tannin-chitosan composite of orally dissolvable thin films as the lead candidate for the development of a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.

Advantages of the orally dissolvable psilocybin thin film technology:

  • Rapid dissolving and onset of action to the bloodstream
  • Ease and convenience for patients to administer
  • No need for water, chewing or swallowing
  • Potential for improved therapeutic outcomes
  • Efficacy for underserved diseases
  • Flexibility to create accurate dosing

The thin film prototypes will undergo further scientific testing including testing of different dosages from 1 mg to 20 mg, physio-chemical characterization (e.g. tensile strength) of composite materials, dissolution and disintegration testing, and rate of psilocybin release from composites.

RVV’s technology aims to deliver both synthetic and natural extract of psilocybin in a potential number of ways such as orally dissolvable thin films, topical gels, creams or ointments, oral or transdermal patches, oral dosages and foams.

The delivery technology is a natural, non-toxic, biodegradable and biocompatible composite.  It has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.

Revive is not a one-trick pony – it has a robust pipe-line of development products.

“Formerly dismissed-by-many pharmaceutical company Revive Therapeutics (RVV.C) jumped a whopping 68% Friday upon revealing it has been granted approval to move forward with phase 3 clinical trials on the use of its Bucillamine medication as a potential treatment for patients with mild to moderate COVID-19,” reported Equity Guru’s Chris Parry on July 27, 2020.

“With the FDA approval of the Phase 3 clinical study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19, our team and partners are working diligently to align our resources and expertise that will fast-track the Phase 3 study,” reported CEO Frank on August 5, 2020.

Revive expects to engage up to 10 clinical trial sites in the U.S. and open the Phase 3 clinical trial for patient screening in Q3-2020.

One of the Canadian patients entering the psilocybin trial, Thomas Hartle, from Saskatoon has stage 4 colon cancer.  He told the Canadian government “there isn’t anything available that can treat existential dread”.

A study by NYU Langone Health revealed that 70% of psilocybin users reported positive life changes after going through the treatment.

“Right now, Revive is one of the early entrants to the burgeoning shrooms/psychedelics/psilocybin industry, a business that is so early it’s not yet legal,” wrote Chris Parry on March 20, 2020, “You could roll your eyes at that, but there are plenty of indicators to suggest the shroom movement will land quicker than medical marijuana did”.

  • Lukas Kane

Full Disclosure: Revive Therapeutics is an Equity Guru marketing client

Written By:

Lukas Kane

Lukas Kane was previously the CEO of a North American investment news syndicate. He was also the Communication Director for a consortium of publicly traded companies. A Senior Writer at Equity.Guru, Mr. Kane writes about mining, cannabis, energy, technology and biotech.

More By This Author
Featured Content
Shroom Boom
5 best Canadian Biotechs
Canadian Biotech
clinical trials
CymaBay Therapeutics (CBAY.NASDAQ)
Investigational new drug
mushroom research
Pharm-Olam LLC
Phase 3 trial
Revive Therapeutics
undervalued bio tech companies
wealth creation
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments